BLC
MCID: BLD134
MIFTS: 79

Bladder Cancer (BLC)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Bladder Cancer

MalaCards integrated aliases for Bladder Cancer:

Name: Bladder Cancer 57 12 53 25 74 37 55 43 15 38
Bladder Carcinoma 12 29 55 6 15 17
Bladder Cancer, Somatic 57 29 13 6
Urinary Bladder Cancer 12 25 74 15
Malignant Neoplasm of Urinary Bladder 72
Urothelial Carcinoma of the Bladder 74
Malignant Tumor of Urinary Bladder 25
Carcinoma of Urinary Bladder 12
Urinary Bladder Neoplasms 44
Cancer of the Bladder 25
Tumor of the Bladder 12
Carcinoma of Bladder 72
Bladder Neoplasm 72
Cancer, Bladder 40
Bladder Tumors 55
Bladder Tumor 17
Blc 74

Characteristics:

OMIM:

57
Inheritance:
somatic mutation


HPO:

32
bladder cancer:
Inheritance autosomal dominant inheritance somatic mutation


Classifications:



External Ids:

Disease Ontology 12 DOID:11054 DOID:4007
OMIM 57 109800
KEGG 37 H00022
ICD9CM 35 188 188.9
MeSH 44 D001749
SNOMED-CT 68 93689003
ICD10 33 C67 C67.9
MedGen 42 C0005684
UMLS 72 C0005684 C0005695 C0699885

Summaries for Bladder Cancer

KEGG : 37
The urothelium covers the luminal surface of almost the entire urinary tract, extending from the renal pelvis, through the ureter and bladder, to the proximal urethra. The majority of urothelial carcinoma are bladder carcinomas, and urothelial carcinomas of the renal pelvis and ureter account for only approximately 7% of the total. Urothelial tumours arise and evolve through divergent phenotypic pathways. Some tumours progress from urothelial hyperplasia to low-grade non-invasive superficial papillary tumours. More aggressive variants arise either from flat, high-grade carcinoma in situ (CIS) and progress to invasive tumours, or they arise de novo as invasive tumours. Low-grade papillary tumors frequently show a constitutive activation of the receptor tyrosine kinase-Ras pathway, exhibiting activating mutations in the HRAS and fibroblast growth factor receptor 3 (FGFR3) genes. In contrast, CIS and invasive tumors frequently show alterations in the TP53 and RB genes and pathways. Invasion and metastases are promoted by several factors that alter the tumour microenvironment, including the aberrant expression of E-cadherins (E-cad), matrix metalloproteinases (MMPs), angiogenic factors such as vascular endothelial growth factor (VEGF).

MalaCards based summary : Bladder Cancer, also known as bladder carcinoma, is related to transitional cell carcinoma and bladder urothelial carcinoma. An important gene associated with Bladder Cancer is FGFR3 (Fibroblast Growth Factor Receptor 3), and among its related pathways/superpathways are Bladder cancer and MicroRNAs in cancer. The drugs Metformin and Pioglitazone have been mentioned in the context of this disorder. Affiliated tissues include urinary bladder, prostate and lymph node, and related phenotype is transitional cell carcinoma of the bladder.

Disease Ontology : 12 An urinary system cancer that results in malignant growth located in the urinary bladder.

Genetics Home Reference : 25 Bladder cancer is a disease in which certain cells in the bladder become abnormal and multiply without control or order. The bladder is a hollow, muscular organ in the lower abdomen that stores urine until it is ready to be excreted from the body. The most common type of bladder cancer begins in cells lining the inside of the bladder and is called transitional cell carcinoma (TCC). Bladder cancer may cause blood in the urine, pain during urination, frequent urination, or the feeling that one needs to urinate without results. These signs and symptoms are not specific to bladder cancer, however. They also can be caused by noncancerous conditions such as infections.

NIH Rare Diseases : 53 Bladder cancer is a form of cancer that occurs due to abnormal and uncontrolled cell growth in the bladder. Signs and symptoms of the condition may include abdominal pain, blood in the urine, fatigue, painful urination, frequent urination, incontinence, and/or weightloss. Most cases of bladder cancer occur sporadically in people with no family history of the condition. Risk factors for the condition include smoking, exposure to certain chemicals, and having chronic bladder infections. Treatment varies based on the severity of the condition and may include surgery, radiation therapy, chemotherapy, and/or biological therapy.

MedlinePlus : 43 The bladder is a hollow organ in your lower abdomen that stores urine. Bladder cancer occurs in the lining of the bladder. It is the sixth most common type of cancer in the United States. Symptoms include Blood in your urine A frequent urge to urinate Pain when you urinate Low back pain Risk factors for developing bladder cancer include smoking and exposure to certain chemicals in the workplace. People with a family history of bladder cancer or who are older, white, or male have a higher risk. Treatments for bladder cancer include surgery, radiation therapy, chemotherapy, and biologic therapy. Biologic therapy boosts your body's own ability to fight cancer. NIH: National Cancer Institute

UniProtKB/Swiss-Prot : 74 Bladder cancer: A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas that begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences.

Wikipedia : 75 Bladder cancer is any of several types of cancer arising from the tissues of the urinary bladder. It is... more...

More information from OMIM: 109800

Related Diseases for Bladder Cancer

Diseases in the Bladder Cancer family:

Bladder Carcinoma in Situ

Diseases related to Bladder Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 880)
# Related Disease Score Top Affiliating Genes
1 transitional cell carcinoma 34.2 HRAS FGFR3 BRINP1
2 bladder urothelial carcinoma 33.3 TUG1 RB1 KRAS HRAS HOTAIR FGFR3
3 adenocarcinoma 32.5 RB1 KRAS HRAS H19 FGFR3
4 renal cell carcinoma, nonpapillary 32.3 UCA1 TUG1 TSC1 HOTAIR H19
5 squamous cell carcinoma 32.2 UCA1 TUG1 RB1 HRAS HOTAIR H19
6 prostate cancer 32.2 UCA1 TUG1 RB1 MIR221 MIR21 MIR143
7 kidney cancer 32.1 MIR21 HOTAIR H19
8 lung cancer 32.0 ZEB2-AS1 UCA1 TUG1 RB1 MIR221 MIR21
9 gallbladder cancer 32.0 UCA1 TUG1 KRAS HOTAIR H19
10 cervical cancer 31.9 UCA1 TUG1 RB1 MIR21 MIR143 HRAS
11 lung cancer susceptibility 3 31.9 TUG1 KRAS HRAS HOTAIR H19 FGFR3
12 colorectal cancer 31.9 UCA1 TUG1 MIR221 MIR21 MIR143 MIR127
13 gastric cancer 31.8 UCA1 TUG1 MIR221 MIR21 MIR143 KRAS
14 glioblastoma 31.8 TUG1 RB1 MIR221 MIR21 MIR10B HRAS
15 hepatocellular carcinoma 31.8 ZEB2-AS1 UCA1 TUG1 RB1 MIR221 MIR21
16 breast cancer 31.7 UCA1 TUG1 RB1 MIR221 MIR21 MIR143
17 myeloma, multiple 31.7 UCA1 TUG1 KRAS HRAS HOTAIR H19
18 esophageal cancer 31.6 UCA1 RB1 MIR21 KRAS HRAS HOTAIR
19 endometrial cancer 31.6 UCA1 TUG1 RB1 KRAS HRAS HOTAIR
20 osteogenic sarcoma 31.6 UCA1 TUG1 RB1 HOTAIR H19
21 pancreatic cancer 31.6 UCA1 TUG1 MIR221 MIR21 MIR143 MIR127
22 lung squamous cell carcinoma 31.5 TUG1 KRAS HRAS FGFR3
23 melanoma 31.5 UCA1 MIR221 MIR127 HOTAIR H19
24 ovarian cancer 31.5 UCA1 TUG1 MIR221 MIR21 MIR143 MIR127
25 cholangiocarcinoma 31.5 UCA1 TUG1 MIR21 KRAS H19
26 thyroid cancer, nonmedullary, 1 31.4 MIR221 HOTAIR H19
27 pancreatic ductal adenocarcinoma 31.3 UCA1 MIR221 MIR21 MIR143 HOTAIR H19
28 intrahepatic cholangiocarcinoma 31.3 TUG1 MIR127 KRAS
29 glioma 31.3 UCA1 MIR221 MIR21 MIR10B HOTAIR H19
30 small cell cancer of the lung 31.3 TUG1 RB1 MIR21 HOTAIR
31 nevus, epidermal 31.2 KRAS HRAS FGFR3
32 squamous cell carcinoma, head and neck 31.2 RB1 MIR221 MIR21 HRAS HOTAIR H19
33 leukemia, chronic myeloid 31.1 UCA1 HRAS HOTAIR H19
34 oral squamous cell carcinoma 31.0 UCA1 TUG1 MIR221 MIR21 MIR143 HOTAIR
35 ovarian epithelial cancer 31.0 HOTAIR H19
36 bladder adenocarcinoma 30.9 UCA1 HRAS
37 diffuse large b-cell lymphoma 30.9 MIR221 MIR21 MIR143 MIR127 HOTAIR
38 polymyositis 30.9 MIR21 MIR127
39 gastric adenocarcinoma 30.4 KRAS HRAS HOTAIR H19
40 superficial urinary bladder cancer 12.4
41 jewett-marshall bladder cancer 12.3
42 bladder cancer, childhood 12.3
43 gall bladder carcinoma in situ 12.2
44 small cell carcinoma of the bladder 12.1
45 chondrodysplasia, blomstrand type 11.9
46 pseudo-torch syndrome 1 11.9
47 urinary bladder small cell neuroendocrine carcinoma 11.8
48 urachal cancer 11.5
49 schistosomiasis 11.5
50 bladder disease 11.4

Comorbidity relations with Bladder Cancer via Phenotypic Disease Network (PDN): (show all 17)


Acute Cystitis Acute Kidney Failure
Bladder Neck Obstruction Cystitis
Cystitis Cystica Deficiency Anemia
Hydronephrosis Neutropenia
Paralytic Ileus Prostate Cancer
Prostatic Hypertrophy Radiation Cystitis
Renal Pelvis Carcinoma Ureter, Cancer of
Urethral Benign Neoplasm Urethral Stricture
Urinary Tract Obstruction

Graphical network of the top 20 diseases related to Bladder Cancer:



Diseases related to Bladder Cancer

Symptoms & Phenotypes for Bladder Cancer

Human phenotypes related to Bladder Cancer:

32
# Description HPO Frequency HPO Source Accession
1 transitional cell carcinoma of the bladder 32 HP:0006740

Symptoms via clinical synopsis from OMIM:

57
Neoplasia:
bladder cancer
transitional cell bladder carcinoma

Clinical features from OMIM:

109800

Drugs & Therapeutics for Bladder Cancer

Drugs for Bladder Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 500)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4 657-24-9 4091 14219
2
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
3
Alverine Approved, Investigational Phase 4 150-59-4 3678
4
Mebeverine Approved, Investigational Phase 4 3625-06-7 62887
5
Gliclazide Approved Phase 4 21187-98-4 3475
6
Glimepiride Approved Phase 4 93479-97-1 3476
7
Glyburide Approved Phase 4 10238-21-8 3488
8
Tranexamic Acid Approved Phase 4 1197-18-8 5526
9
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
10
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
11
Parecoxib Approved Phase 4 198470-84-7
12
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
13
Tamsulosin Approved, Investigational Phase 4 106133-20-4 129211
14
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
15
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
16
Ofloxacin Approved Phase 4 82419-36-1 4583
17
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
18
Piroxicam Approved, Investigational Phase 4 36322-90-4 5280452 54676228
19
Lornoxicam Approved, Investigational Phase 4 70374-39-9 5282204
20
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
21
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
22
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 11103-57-4, 68-26-8 9904001 445354
23
Beta carotene Approved, Nutraceutical Phase 4 7235-40-7
24
2,4-thiazolidinedione Investigational Phase 4 2295-31-0
25
Fibrinolysin Investigational Phase 4 9004-09-5
26 Hypoglycemic Agents Phase 4
27 Cephalosporins Phase 4
28 Parasympatholytics Phase 4
29 Psychotropic Drugs Phase 4
30 Cyclooxygenase 2 Inhibitors Phase 4
31 Plasminogen Phase 4
32 Nicotinic Agonists Phase 4
33 Central Nervous System Stimulants Phase 4
34 Antifibrinolytic Agents Phase 4
35 Antidepressive Agents Phase 4
36 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
37 Antidepressive Agents, Second-Generation Phase 4
38 Dopamine Agents Phase 4
39 Neurotransmitter Uptake Inhibitors Phase 4
40 Dopamine Uptake Inhibitors Phase 4
41 lysine Phase 4
42 Carotenoids Phase 4
43 retinol Phase 4
44 Retinol palmitate Phase 4
45 Provitamins Phase 4
46 Adrenergic alpha-1 Receptor Antagonists Phase 4
47 Adrenergic alpha-Antagonists Phase 4
48 Adrenergic Antagonists Phase 4
49 Adrenergic Agents Phase 4
50 Neurotransmitter Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 1209)
# Name Status NCT ID Phase Drugs
1 The Assessment of Postoperative Cognitive Dysfunction After Transurethral Resection of Bladder Tumor Under Spinal Anesthesia Unknown status NCT03029676 Phase 4 benzodiazepines;opioid
2 Ultrasound-Guided Obturator Nerve Block for Transurethral Procedures - Interadductor Approach Unknown status NCT02696733 Phase 4 lidocaine 2%;0.9% Natrium Chloratum with a 2nd generation cephalosporin
3 Influence of Immune Nutrition Diet on 90-Day Outcomes in Patients Undergoing Radical Cystectomy and Bladder Substitutions: A Randomized Controlled Trial Unknown status NCT03147586 Phase 4 Bio-tech and omega-3 plus;placebo
4 Comparation the Effect of C-LMA and I-gel in Regurgitation and Postoperative Complications Unknown status NCT01876836 Phase 4
5 Mebeverine For Daytime And Nocturnal Incontinence and After Orthotopic W-Ileal Neobladders - Assessment Of Efficacy And Quality Of Life Effect Within 1 Year Post-Surgery: A Randomized Cross-over Controlled Study Unknown status NCT03147599 Phase 4 Coloverin;Placebo
6 Effects on Incidence of Cardiovascular Events of the Addition of Pioglitazone as Compared With a Sulphonylurea in Type 2 Diabetic Patients Inadequately Controlled With Metformin. Unknown status NCT00700856 Phase 4 add-on pioglitazone;add-on sulphonylurea
7 The Value of Immediate Post-operative Intravesical Epirubicin Instillation in Intermediate and High Risk Non Muscle Invasive Bladder Cancer (NMIBC): A Randomized Controlled Trial Completed NCT02214602 Phase 4 Epirubicin
8 In the Prediction of Recurrence and Progression of NMIBC; EORTC or CUETO or Both? Completed NCT03174912 Phase 4
9 The Effect of Neuromuscular Blockade During Transurethral Resection of Bladder Cancer on Surgical Condition and Recovery Profiles : A Prospective, Randomized and Controlled Trial Completed NCT03039543 Phase 4 Rocuronium;Sugammadex
10 Effect of TachoSil® on Incidence of Symptomatic and Radiographic Lymphoceles After Extended Pelvic Lymph Node Dissection in Prostate and Bladder Cancer. Completed NCT02001857 Phase 4 1 TachoSil hemostatic sponge (9,5 cm x 4,8 cm) placed on each side on the external iliac artery.
11 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
12 Safety and Efficacy of Intravenous Tranexamic Acid in Reducing Blood Transfusion After Endoscopic Transurethral Resections in Urology: A Prospective, Randomized, Double-Blind, Placebo-Controlled Study Completed NCT02653261 Phase 4 Tranexamic Acid;Placebo
13 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
14 Efficacy and Tolerance of Parecoxib for Prevention of Catheter-related Bladder Discomfort in Patients Undergoing Catheterization After TURBT: A Prospective, Randomized, Placebo-controlled, Double-blind Study Completed NCT02729935 Phase 4 Parecoxib;Placebo
15 Caret and Retinol Efficacy Trial: The Caret Coordinating Center Completed NCT00712647 Phase 4 Beta Carotene and Retinol
16 A Simple Oral Nutrition Protocol Reduces Length of Stay in Patients With Regular Radical Cystectomy Completed NCT01777126 Phase 4
17 Comparison of Medical and Surgical Treatments of Benign Prostate Hyperplasia in Patients Who Have Low Grade Non Muscle Invasive Bladder Cancer for Tumour Recurrence and Progression Recruiting NCT02443844 Phase 4 Tamsulosin
18 The Effect of Preemptive Analgesia On The Comfort Of Patient and Doctor, in Cystoscopy Recruiting NCT03831321 Phase 4 Diclofenac Sodium;Lubricant Gel
19 Impact of Hyperoncotic Albumin to Support Blood Loss Replacement on Plasma Volume Expansion in Cystectomy Patients. Recruiting NCT03848507 Phase 4 albumin 20%
20 Solifenacin vs Levofloxacin vs Lornoxicam for Management of Intravesical Instillation of Bacillus Calmette-Guerin (BCG) Side Effects A Single Blinded Randomised Controlled Study Active, not recruiting NCT03038321 Phase 4 sofenacin;Tavanic;Xefo
21 A Phase IV Investigation of Sugammadex in Outpatient Urological Procedures Active, not recruiting NCT03138967 Phase 4 Rocuronium;Sugammadex;Neostigmine;Glycopyrrolate
22 Neoadjuvant Short-term Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in NMIBC Active, not recruiting NCT03348969 Phase 4 Mitomycin c
23 Comparison of the Pathological Stage and Clinical Outcome of en Bloc Transurethral Resection by HybridKnife or Laser Versus Conventional Transurethral Resection for NMIBC: a Prospective, Single Centre, Randomized Study Not yet recruiting NCT03221062 Phase 4
24 Chemoradiotherapy for Recurrent T1G3 Bladder Cancer After BCG Failure Not yet recruiting NCT03274284 Phase 4
25 The Effects of Sequential Mitomycin and Bacillus Calmette-Guérin Treatment Versus Bacillus Calmette-Guérin Monotherapy in Patients With High Risk Non-Muscle Invasive Bladder Cancer Not yet recruiting NCT03790384 Phase 4 Mitomycin
26 Must Aspirin be Discontinued Prior to TURBT: a Prospective, Randomized, Non-inferiority Trial Comparing Peri-operative Aspirin Continuation Versus Discontinuation. Terminated NCT02350543 Phase 4 Aspirin
27 Recurrence of Bladder Cancer After Transurethral Resection With Hexvix Withdrawn NCT00785694 Phase 4 hexaminolevulinate
28 Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in Subjects With Schistosomiasis: A Pilot Study Withdrawn NCT02734186 Phase 4 Praziquantel
29 A Prospective, Open-label Randomized Clinical Trial of a Single Bladder Instillation of Mitomycin C vs. Gemcitabine vs. No Additional Treatment Immediately After Transurethral Resection of Bladder Tumor (TURBT) Unknown status NCT02695771 Phase 3 Mitomycin C;Gemcitabine
30 Phase III Randomized Study of a Single Adjunctive Instillation of Intravesical AD 32 (N-Trifluoroacetyladriamycin-14-valerate) Versus No Adjunctive Therapy Immediately Following Transurethral Resection in Patients With Multiple Superficial (Ta/T1) Bladder Tumors Unknown status NCT00003725 Phase 3 valrubicin
31 Bladder Cancer Prognosis Programme (Incorporating SELENIB Trial) Unknown status NCT00553124 Phase 3 selenium;vitamin E
32 Using Biploar Technology for Transurethral Resection of Bladder Tumor - a Randomized Controlled Trial Unknown status NCT01581723 Phase 3
33 Bladder Cancer Prognosis Programme (Incorporating SELENIB Trial) [TREATMENT] Unknown status NCT00553345 Phase 3 selenium;vitamin E
34 Neobladder Posterior Wall Suspended With Round Ligament of Uterus After Radical Cystectomy in Female With Bladder Cancer —a Prospective Control Study Unknown status NCT01273987 Phase 2, Phase 3
35 A Study of Comparing Effects of Thulium Laser en Bloc Resection and Electrical Transurethral Resection of the Non-muscle Invasive Bladder Cancer Unknown status NCT02951078 Phase 3
36 Adjuvant Chemotherapy Following Radical Cystectomy to Treat Locally Advanced Bladder Cancer Unknown status NCT02074189 Phase 3 Gemcitabine, Cisplatin
37 The Efficacy of Distilled Water vs Mitomycin C as a Single Dose Immediate Instillation After Transurethral Resection of Intermediate Risk, Recurrent Superficial Bladder Cancer Unknown status NCT00816075 Phase 2, Phase 3 distilled water
38 Efficacy of Diclofenac Suppositories in Prevention of Immediate Side Effects of BCG Bladder Irrigations. A Double Blind Placebo Controlled Randomized Study Unknown status NCT01542567 Phase 3 Abitren;Placebo
39 A Phase II/III, Randomised, Two-Arm, Comparison of Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With HER1 and/or HER2 Overexpressing Locally Advanced or Metastatic Bladder Cancer [LaMB] Unknown status NCT00949455 Phase 2, Phase 3 lapatinib ditosylate
40 The Impact of Early Feeding After Radical Cystectomy for Bladder Cancer Unknown status NCT01489800 Phase 3
41 Phase III Study Of Adjuvant Cisplatin-Gemcitabine Vs. Observation After Radical Cystectomy In High-Risk Bladder Cancer Unknown status NCT00054626 Phase 3 cisplatin;gemcitabine hydrochloride
42 HYMN: A Randomized Controlled Phase III Trial Comparing Hyperthermia Plus Mitomycin to a Second Course of Bacillus Calmette-Guerin or Standard Therapy in Patients With Recurrence of Non-Muscle Invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guerin Therapy Unknown status NCT01094964 Phase 3 epirubicin hydrochloride;mitomycin C
43 Adjuvant vs. Progression-Triggered Treatment With Gemcitabine After Radical Cystectomy for Locally Advanced Transitional Cell Carcinoma of the Bladder in Patients Not Suitable for Cisplatin-Based Chemotherapy - A Phase 3 Study Unknown status NCT00146276 Phase 3 gemcitabine
44 Randomized Double-Blind Controlled Phase III Trial of Hyperbaric Oxygen Therapy in Patients Suffering Long-Term Adverse Effects of Radiotherapy for Pelvic Cancer (HOT II) Unknown status NCT01087268 Phase 3
45 A Multi-centre Randomised Controlled Double-blinded Trial of BCG and Interferon Alpha in High Risk Superficial Bladder Cancer Completed NCT00330707 Phase 2, Phase 3 Bacillus Calmette Guerin and interferon alpha
46 A Randomised Trial of Radical Chemo/Radiotherapy vs Radiotherapy Alone in the Definitive Management of Localised Muscle Invasive TCC of the Urinary Bladder Completed NCT00330499 Phase 3 Cisplatin
47 A Phase III Blinded Study of Immediate Post TURBT Instillation of Gemcitabine Versus Saline in Patients With Newly Diagnosed or Occasionally Recurring Grade I/II Superficial Bladder Cancer Completed NCT00445601 Phase 3 gemcitabine hydrochloride
48 Open-label, Multi-center Study of the Efficacy and Safety of MCC in the Treatment of Patients With Non-muscle Invasive (Superficial) Bladder Cancer at High Risk of Progression and Who Are Refractory to BCG Completed NCT00406068 Phase 2, Phase 3 Mycobacterial cell wall-DNA complex
49 Phase IIb/III Chemoprevention Trial of Celecoxib to Prevent Recurrence of Superficial Bladder Cancer Completed NCT00006124 Phase 2, Phase 3 celecoxib;placebo
50 Noninvasive Detection of Clinically Occult Lymph Node Metastases in Prostate and Bladder Cancer Evaluated by USPIO-Enhanced MRI and Diffusion-Weighted MRI: A Histopathological Correlation Completed NCT00622973 Phase 3

Search NIH Clinical Center for Bladder Cancer

Inferred drug relations via UMLS 72 / NDF-RT 51 :


BCG Vaccine
Carboplatin
Cisplatin
CISPLATIN PWDR
doxorubicin hydrochloride liposome
Etoposide
etoposide phosphate
Ifosfamide
Leucovorin
Methotrexate
Mitomycin
pembrolizumab
Thiotepa
Vinblastine

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Bladder Cancer cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Bladder Cancer:
Neo-Urinary Conduit, smooth muscle cell 3D culture for bladder diseases
Embryonic/Adult Cultured Cells Related to Bladder Cancer:
Neo-Urinary Conduit PMIDs: 22136657

Cochrane evidence based reviews: urinary bladder neoplasms

Genetic Tests for Bladder Cancer

Genetic tests related to Bladder Cancer:

# Genetic test Affiliating Genes
1 Bladder Cancer, Somatic 29 FGFR3 HRAS KRAS RB1
2 Bladder Carcinoma 29

Anatomical Context for Bladder Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Bladder Cancer:

19
Urinary Bladder

MalaCards organs/tissues related to Bladder Cancer:

41
Prostate, Lymph Node, Testes, Lung, Kidney, T Cells, Endothelial

Publications for Bladder Cancer

Articles related to Bladder Cancer:

(show top 50) (show all 34449)
# Title Authors PMID Year
1
Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. 8 71
10471491 1999
2
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. 38 8
25428503 2014
3
Frequent truncating mutations of STAG2 in bladder cancer. 38 8
24121789 2013
4
Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. 38 8
24121791 2013
5
Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. 38 8
24121792 2013
6
Genome sequencing identifies a basis for everolimus sensitivity. 38 8
22923433 2012
7
Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. 38 8
21822268 2011
8
Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. 38 8
20591884 2010
9
A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. 38 8
20348956 2010
10
Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. 38 8
18794855 2008
11
Mitochondrial cytochrome B gene mutation promotes tumor growth in bladder cancer. 38 8
18245469 2008
12
Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. 38 8
16465622 2006
13
Identifying distinct classes of bladder carcinoma using microarrays. 38 8
12469123 2003
14
Cytogenetics and molecular genetics of bladder cancer: a personal view. 38 8
12407698 2002
15
Familial transitional cell carcinoma. 38 8
8709350 1996
16
Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. 38 8
7757072 1995
17
Definition of two regions of deletion on chromosome 9 in carcinoma of the bladder. 38 8
8208555 1994
18
Loss of heterozygosity on chromosome 11p13 in primary bladder carcinoma. 38 8
8100210 1993
19
Clonal origin of bladder cancer. 38 8
1445507 1992
20
Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. 9 71
2181449 1990
21
Allelic losses of chromosomes 9, 11, and 17 in human bladder cancer. 38 8
2293558 1990
22
Loss of genes on the short arm of chromosome 11 in bladder cancer. 38 71
2999610 1985
23
Oncogene from human EJ bladder carcinoma is located on the short arm of chromosome 11. 38 8
6297001 1983
24
Activation of the T24 bladder carcinoma transforming gene is linked to a single amino acid change. 38 71
7177195 1982
25
Isolation and preliminary characterization of a human transforming gene from T24 bladder carcinoma cells. 38 8
7063039 1982
26
Familial aggregation of urothelial carcinoma. 38 8
7053069 1981
27
Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. 38 8
7207618 1981
28
Transforming activity of human tumor DNAs. 38 8
6940134 1981
29
Familial factors in bladder carcinoma. 38 8
480484 1979
30
Abnormal tryptophan metabolism in a family with a history of bladder cancer. 38 8
994212 1976
31
Management of metastatic bladder cancer. 38 17
31030123 2019
32
Urologic Malignancies. 38 17
31030829 2019
33
Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer. 8
25722414 2015
34
Keratinocytic epidermal nevi are associated with mosaic RAS mutations. 71
22499344 2012
35
MicroRNA-221 silencing predisposed human bladder cancer cells to undergo apoptosis induced by TRAIL. 38 88
19767219 2010
36
A microRNA expression ratio defining the invasive phenotype in bladder tumors. 38 88
18799331 2010
37
Distinct microRNA alterations characterize high- and low-grade bladder cancer. 38 88
19843843 2009
38
MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. 9 88
19593777 2009
39
Identification of novel microRNA targets based on microRNA signatures in bladder cancer. 38 88
19378336 2009
40
Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. 38 88
19487295 2009
41
MicroRNA-143 as a tumor suppressor for bladder cancer. 38 88
19157460 2009
42
Acanthosis nigricans in a child with mild osteochondrodysplasia and K650Q mutation in the FGFR3 gene. 71
18000903 2007
43
Micro-RNA profiling in kidney and bladder cancers. 38 88
17826655 2007
44
Myopathy caused by HRAS germline mutations: implications for disturbed myogenic differentiation in the presence of constitutive HRas activation. 71
17412879 2007
45
Novel FGFR3 mutations creating cysteine residues in the extracellular domain of the receptor cause achondroplasia or severe forms of hypochondroplasia. 71
16912704 2006
46
Germline mutations in HRAS proto-oncogene cause Costello syndrome. 71
16170316 2005
47
Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. 71
15772091 2005
48
Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma. 71
11314002 2001
49
Distinct missense mutations of the FGFR3 lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype. 71
11055896 2000
50
Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. 8
10720328 2000

Variations for Bladder Cancer

ClinVar genetic disease variations for Bladder Cancer:

6 (show top 50) (show all 84)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 MRE11 NM_005591.3(MRE11): c.545-297G> T single nucleotide variant other rs118024137 11:94209866-94209866 11:94476700-94476700
2 MRE11 NM_005591.3(MRE11): c.314+99A> G single nucleotide variant other rs143677623 11:94218991-94218991 11:94485825-94485825
3 MRE11 NM_005591.3(MRE11): c.20+821G> A single nucleotide variant other rs397509351 11:94225127-94225127 11:94491961-94491961
4 MRE11 NM_005591.3(MRE11): c.1784-438A> G single nucleotide variant other rs397509358 11:94179497-94179497 11:94446331-94446331
5 MRE11 NM_005591.3(MRE11): c.1783+561G> A single nucleotide variant other rs397509357 11:94179824-94179824 11:94446658-94446658
6 MRE11 NM_005591.3(MRE11): c.1327-461A> C single nucleotide variant other rs185485357 11:94193208-94193208 11:94460042-94460042
7 MRE11 NM_005591.3(MRE11): c.1225+804T> C single nucleotide variant other rs397509356 11:94196475-94196475 11:94463309-94463309
8 MRE11 NM_005591.3(MRE11): c.1225+605T> C single nucleotide variant other rs397509355 11:94196674-94196674 11:94463508-94463508
9 MRE11 NM_005591.3(MRE11): c.1225+577A> C single nucleotide variant other rs397509354 11:94196702-94196702 11:94463536-94463536
10 MRE11 NM_005591.3(MRE11): c.1225+572A> T single nucleotide variant other rs397509353 11:94196707-94196707 11:94463541-94463541
11 MRE11 NM_005591.3(MRE11): c.1225+40T> C single nucleotide variant other rs192979170 11:94197239-94197239 11:94464073-94464073
12 MRE11 NM_005591.3(MRE11): c.1098+1408A> G single nucleotide variant other rs200367125 11:94199571-94199571 11:94466405-94466405
13 MRE11 NM_005591.3(MRE11): c.1098+1177G> A single nucleotide variant other rs369782842 11:94199802-94199802 11:94466636-94466636
14 MRE11 NM_005591.3(MRE11): c.-105-387C> T single nucleotide variant other rs397509350 11:94226459-94226459 11:94493293-94493293
15 MRE11 NM_005591.3(MRE11): c.-105-326A> T single nucleotide variant other rs183829476 11:94226398-94226398 11:94493232-94493232
16 MRE11 NM_005591.3(MRE11): c.*631C> T single nucleotide variant other rs397509347 11:94152660-94152660 11:94419494-94419494
17 MRE11 NM_005591.3(MRE11): c.*570A> C single nucleotide variant other rs397509346 11:94152721-94152721 11:94419555-94419555
18 MRE11 NM_005591.3(MRE11): c.*2731G> A single nucleotide variant other rs397509349 11:94150560-94150560 11:94417394-94417394
19 MRE11 NM_005591.3(MRE11): c.*1359T> C single nucleotide variant other rs397509348 11:94151932-94151932 11:94418766-94418766
20 MRE11 NM_005591.3(MRE11): c.1098+614C> T single nucleotide variant other rs140067184 11:94200365-94200365 11:94467199-94467199
21 MRE11 NM_005591.3(MRE11): c.1098+1620T> C single nucleotide variant other rs397509352 11:94199359-94199359 11:94466193-94466193
22 MRE11 NM_005591.3(MRE11): c.1563+281G> A single nucleotide variant other rs397509429 11:94189161-94189161 11:94455995-94455995
23 FGFR3 NM_000142.4(FGFR3): c.1949A> C (p.Lys650Thr) single nucleotide variant Pathogenic rs121913105 4:1807890-1807890 4:1806163-1806163
24 KRAS NM_004985.5(KRAS): c.458A> T (p.Asp153Val) single nucleotide variant Pathogenic rs104894360 12:25362838-25362838 12:25209904-25209904
25 FGFR3 NM_000142.4(FGFR3): c.1948A> C (p.Lys650Gln) single nucleotide variant Pathogenic rs78311289 4:1807889-1807889 4:1806162-1806162
26 FGFR3 NM_000142.4(FGFR3): c.1108G> T (p.Gly370Cys) single nucleotide variant Pathogenic rs121913479 4:1806089-1806089 4:1804362-1804362
27 TSC1 NM_000368.4(TSC1): c.2074C> T (p.Arg692Ter) single nucleotide variant Pathogenic rs118203631 9:135779172-135779172 9:132903785-132903785
28 TSC1 NM_000368.4(TSC1): c.1905_1906AG[1] (p.Glu636fs) short repeat Pathogenic rs118203599 9:135781057-135781058 9:132905670-132905671
29 TSC1 NM_000368.4(TSC1): c.1525C> T (p.Arg509Ter) single nucleotide variant Pathogenic rs118203542 9:135781440-135781440 9:132906053-132906053
30 RB1 NM_000321.2(RB1): c.1981C> T (p.Arg661Trp) single nucleotide variant Pathogenic rs137853294 13:49033844-49033844 13:48459708-48459708
31 RB1 RB1, IVS20, A-G, -2 single nucleotide variant Pathogenic
32 HRAS NM_005343.4(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 11:534289-534289 11:534289-534289
33 HRAS NM_005343.4(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 11:534286-534286 11:534286-534286
34 HRAS NM_005343.4(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 11:534288-534288 11:534288-534288
35 HRAS NM_005343.4(HRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic rs104894230 11:534288-534288 11:534288-534288
36 KRAS NM_004985.5(KRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913530 12:25398285-25398285 12:25245351-25245351
37 FGFR3 NM_000142.4(FGFR3): c.742C> T (p.Arg248Cys) single nucleotide variant Pathogenic rs121913482 4:1803564-1803564 4:1801837-1801837
38 FGFR3 NM_000142.4(FGFR3): c.1111A> T (p.Ser371Cys) single nucleotide variant Pathogenic rs121913484 4:1806092-1806092 4:1804365-1804365
39 FGFR3 NM_000142.4(FGFR3): c.1620C> G (p.Asn540Lys) single nucleotide variant Pathogenic rs28933068 4:1807371-1807371 4:1805644-1805644
40 FGFR3 NM_000142.4(FGFR3): c.746C> G (p.Ser249Cys) single nucleotide variant Pathogenic rs121913483 4:1803568-1803568 4:1801841-1801841
41 FGFR3 NM_000142.4(FGFR3): c.749C> G (p.Pro250Arg) single nucleotide variant Pathogenic rs4647924 4:1803571-1803571 4:1801844-1801844
42 RB1 NM_000321.2(RB1): c.1215+1G> A single nucleotide variant Pathogenic rs587776783 13:48947629-48947629 13:48373493-48373493
43 TSC1 NM_000368.4(TSC1): c.1579C> T (p.Gln527Ter) single nucleotide variant Pathogenic/Likely pathogenic rs118203549 9:135781386-135781386 9:132905999-132905999
44 TSC1 NM_000368.4(TSC1): c.664-1G> A single nucleotide variant Pathogenic/Likely pathogenic rs118203423 9:135796824-135796824 9:132921437-132921437
45 TSC1 NM_000368.4(TSC1): c.663+1G> A single nucleotide variant Pathogenic/Likely pathogenic rs118203419 9:135797205-135797205 9:132921818-132921818
46 FGFR3 NM_000142.4(FGFR3): c.2089G> T (p.Gly697Cys) single nucleotide variant Likely pathogenic rs121913480 4:1808331-1808331 4:1806604-1806604
47 FGFR3 NM_000142.4(FGFR3): c.1118A> G (p.Tyr373Cys) single nucleotide variant Conflicting interpretations of pathogenicity rs121913485 4:1806099-1806099 4:1804372-1804372
48 TSC1 NM_000368.4(TSC1): c.1250C> T (p.Thr417Ile) single nucleotide variant Conflicting interpretations of pathogenicity rs77464996 9:135785971-135785971 9:132910584-132910584
49 TSC1 NM_000368.4(TSC1): c.2646C> T (p.Ala882=) single nucleotide variant Conflicting interpretations of pathogenicity rs118203720 9:135772977-135772977 9:132897590-132897590
50 FGFR3 NM_000142.4(FGFR3): c.1138G> A (p.Gly380Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs28931614 4:1806119-1806119 4:1804392-1804392

UniProtKB/Swiss-Prot genetic disease variations for Bladder Cancer:

74
# Symbol AA change Variation ID SNP ID
1 FGFR3 p.Arg248Cys VAR_004148 rs121913482
2 FGFR3 p.Ser249Cys VAR_004149 rs121913483
3 FGFR3 p.Gly370Cys VAR_004151 rs121913479
4 FGFR3 p.Lys650Glu VAR_004160 rs78311289
5 FGFR3 p.Lys650Gln VAR_018390 rs78311289

Cosmic variations for Bladder Cancer:

9 (show top 50) (show all 8042)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6933774 ZRSR2 urinary tract,bladder,carcinoma,transitional cell carcinoma c.965G>A p.R322K 23:15822758-15822758 4
2 COSM6933517 ZRSR2 urinary tract,bladder,carcinoma,transitional cell carcinoma c.946G>C p.E316Q 23:15822739-15822739 4
3 COSM6929526 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.8376G>A p.M2792I 16:72794306-72794306 4
4 COSM6975086 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.8390G>T p.R2797I 16:72794292-72794292 4
5 COSM6977171 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.5645T>A p.I1882N 16:72797037-72797037 4
6 COSM6949043 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.2249A>G p.H750R 16:72957897-72957897 4
7 COSM6962516 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.9829C>T p.P3277S 16:72788447-72788447 4
8 COSM6966832 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.2230C>T p.H744Y 16:72957916-72957916 4
9 COSM6929527 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.808G>A p.D270N 16:72959338-72959338 4
10 COSM4062699 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.9812C>T p.T3271M 16:72788464-72788464 4
11 COSM6934820 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.49G>A p.G17S 16:72960097-72960097 4
12 COSM6958276 ZFHX3 urinary tract,urethra,carcinoma,adenocarcinoma c.8649G>T p.M2883I 16:72794033-72794033 4
13 COSM6986820 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.7253C>T p.T2418I 16:72795429-72795429 4
14 COSM6954831 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.1907C>T p.S636L 16:72958239-72958239 4
15 COSM6937946 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.5886G>T p.E1962D 16:72796796-72796796 4
16 COSM6967093 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.883C>T p.R295C 16:72959263-72959263 4
17 COSM6965513 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.8711A>G p.K2904R 16:72793971-72793971 4
18 COSM6976091 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.4937C>T p.S1646F 16:72797745-72797745 4
19 COSM6971431 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.11065A>T p.K3689* 16:72787211-72787211 4
20 COSM4499983 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.554C>T p.S185L 16:72959592-72959592 4
21 COSM6503148 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.2458C>T p.R820C 16:72957688-72957688 4
22 COSM6933052 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.625G>A p.E209K 16:72959521-72959521 4
23 COSM6937948 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.4817G>A p.S1606N 16:72797865-72797865 4
24 COSM4600074 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.10826C>T p.S3609F 16:72787450-72787450 4
25 COSM6975088 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.5416G>C p.E1806Q 16:72797266-72797266 4
26 COSM6928012 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.7799C>G p.S2600* 16:72794883-72794883 4
27 COSM6969901 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.10802C>T p.S3601L 16:72787474-72787474 4
28 COSM6977172 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.308G>A p.R103H 16:72959838-72959838 4
29 COSM6943037 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.6910C>T p.Q2304* 16:72795772-72795772 4
30 COSM6937945 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.10403G>A p.R3468H 16:72787873-72787873 4
31 COSM3276825 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.6608G>A p.R2203H 16:72796074-72796074 4
32 COSM6934510 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.10573G>A p.G3525S 16:72787703-72787703 4
33 COSM1640552 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.8849G>A p.R2950H 16:72793833-72793833 4
34 COSM6975375 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.9127A>G p.I3043V 16:72793555-72793555 4
35 COSM6986819 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.10015G>C p.E3339Q 16:72788261-72788261 4
36 COSM973504 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.8029G>A p.E2677K 16:72794653-72794653 4
37 COSM6926924 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.9964C>T p.Q3322* 16:72788312-72788312 4
38 COSM6954830 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.2434G>C p.E812Q 16:72957712-72957712 4
39 COSM6986821 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.151G>A p.D51N 16:72959995-72959995 4
40 COSM6975087 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.7576C>T p.Q2526* 16:72795106-72795106 4
41 COSM6937947 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.4880C>T p.A1627V 16:72797802-72797802 4
42 COSM1379719 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.4595A>G p.N1532S 16:72798087-72798087 4
43 COSM6931485 YES1 urinary tract,bladder,carcinoma,transitional cell carcinoma c.460C>G p.Q154E 18:747930-747930 4
44 COSM6920698 YES1 urinary tract,bladder,carcinoma,transitional cell carcinoma c.595C>T p.R199C 18:745837-745837 4
45 COSM6981599 YES1 urinary tract,bladder,carcinoma,transitional cell carcinoma c.1342C>T p.R448W 18:732915-732915 4
46 COSM6926471 YAP1 urinary tract,bladder,carcinoma,transitional cell carcinoma c.182C>G p.S61W 11:102111030-102111030 4
47 COSM6940397 YAP1 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.1086C>A p.F362L 11:102227553-102227553 4
48 COSM6937766 XRCC2 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.151G>A p.G51R 7:152649334-152649334 4
49 COSM3054551 XPO1 urinary tract,bladder,carcinoma,transitional cell carcinoma c.948G>C p.Q316H 2:61495554-61495554 4
50 COSM6918440 XPO1 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.2668G>A p.A890T 2:61483946-61483946 4

Copy number variations for Bladder Cancer from CNVD:

7 (show top 50) (show all 98)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 16660 1 128900000 185800000 Gain Bladder cancer
2 36534 1 77068898 77170790 Loss Bladder cancer
3 51778 11 130615965 132678521 Loss Bladder cancer
4 53648 11 31517796 32050223 Loss Bladder cancer
5 58531 11 68323054 69297218 Gain Bladder cancer
6 80757 13 97270228 100084626 Gain Bladder cancer
7 81341 14 101619009 102408085 Loss Bladder cancer
8 83177 14 19364851 19446107 Loss Bladder cancer
9 87829 14 77750645 79747731 Loss Bladder cancer
10 88246 14 88632756 89467875 Gain Bladder cancer
11 89915 15 19427350 19427409 Loss Bladder cancer
12 96847 15 95052889 95403459 Loss Bladder cancer
13 97491 16 10647794 11795463 Gain Bladder cancer
14 101674 16 45413780 45607724 Gain Bladder cancer
15 107647 17 1649595 1725887 Loss Bladder cancer
16 112300 17 38521264 78444637 Gain Bladder cancer
17 118108 17 7571719 7590863 Loss TP53 Bladder cancer
18 121742 18 467310 796252 Gain Bladder cancer
19 122814 18 61643142 67432063 Loss Bladder cancer
20 126424 19 18749534 19294814 Gain Bladder cancer
21 127148 19 278073 12616127 Gain Bladder cancer
22 135679 2 11956730 12796508 Gain Bladder cancer
23 135959 2 123437325 126399586 Loss Bladder cancer
24 138231 2 159948195 160120757 Loss Bladder cancer
25 141850 2 217249378 242464793 Loss Bladder cancer
26 146581 2 51236117 51635693 Loss Bladder cancer
27 147190 2 60966923 61033726 Loss Bladder cancer
28 147284 2 62081310 62298660 Loss Bladder cancer
29 148163 2 74469 50579433 Loss Bladder cancer
30 150320 2 9872881 10505097 Gain Bladder cancer
31 150974 20 157771 456225 Gain Bladder cancer
32 151125 20 17870221 18440898 Gain Bladder cancer
33 151502 20 22093371 26036562 Gain Bladder cancer
34 152003 20 28081598 47163674 Gain Bladder cancer
35 164078 22 34482413 35495073 Gain Bladder cancer
36 167750 3 12328914 12396406 Gain Bladder cancer
37 170412 3 153906953 155170944 Gain Bladder cancer
38 170822 3 159876217 162162404 Gain Bladder cancer
39 171019 3 162425422 164314793 Gain Bladder cancer
40 176797 3 50653920 52539982 Loss Bladder cancer
41 179967 4 1 4500000 Loss Bladder cancer
42 186746 4 38697312 42182524 Loss Bladder cancer
43 193888 5 134523261 135051953 Loss Bladder cancer
44 200115 5 50094582 74360979 Loss Bladder cancer
45 202946 5 90316808 90788310 Loss Bladder cancer
46 203715 6 1 61000000 Gain Bladder cancer
47 204149 6 107127877 107503845 Loss Bladder cancer
48 204292 6 108783383 109034288 Loss Bladder cancer
49 204477 6 11110371 17397320 Gain Bladder cancer
50 205260 6 123251233 125408147 Loss Bladder cancer

Expression for Bladder Cancer

Search GEO for disease gene expression data for Bladder Cancer.

Pathways for Bladder Cancer

Pathways related to Bladder Cancer according to KEGG:

37
# Name Kegg Source Accession
1 Bladder cancer hsa05219
2 MicroRNAs in cancer hsa05206

GO Terms for Bladder Cancer

Biological processes related to Bladder Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.77 TSC1 RB1 MIR221 MIR21 HRAS
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.73 MIR221 MIR21 HRAS FGFR3
3 Ras protein signal transduction GO:0007265 9.58 RB1 KRAS HRAS
4 positive regulation of protein kinase B signaling GO:0051897 9.56 MIR221 MIR21 MIR143 FGFR3
5 striated muscle cell differentiation GO:0051146 9.46 RB1 KRAS
6 gene silencing by miRNA GO:0035195 9.43 MIR221 MIR21 MIR143 MIR127 MIR10B H19
7 negative regulation of GTPase activity GO:0034260 9.33 TSC1 MIR21 HRAS
8 response to isolation stress GO:0035900 9.32 KRAS HRAS
9 positive regulation of vascular associated smooth muscle cell migration GO:1904754 8.8 MIR221 MIR21 MIR143

Molecular functions related to Bladder Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 8.92 MIR221 MIR21 MIR143 MIR10B

Sources for Bladder Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....